Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

被引：0
|
作者：
Brian R. Ott
Lesley M. Blake
Ethel Kagan
Malca Resnick
机构：
[1] Rhode Island Hospital – APC 6,The Alzheimer’s Disease & Memory Disorders Center
[2] Northwestern University,Department of Psychiatry
[3] Harborside Financial Center,Forest Laboratories, Inc.
来源：
Journal of Neurology | 2007年 / 254卷
关键词：
Alzheimer’s disease; memantine; open label; randomized controlled trial; ADAS-cog;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 358
页数：7
相关论文
共 50 条
  • [31] Safety and efficacy of donepezil in a 12-week, open-label trial in African Americans with mild to moderate Alzheimer's disease
    Griffith, P
    Lichtenberg, P
    Goldman, R
    Payne-Parrish, J
    Richardson, S
    NEUROLOGY, 2005, 64 (06) : A366 - A366
  • [32] A 52-week open-label study to investigate tolerability of rivastigmine switching from oral capsule to transdermal patch in mild to moderate Alzheimer's disease patients in Taiwan
    Fuh, J. L.
    Chen, T. F.
    Lan, T. H.
    Yang, Y. W.
    Tsai, C. F.
    Chuo, L. J.
    Wang, P. N.
    Chiu, M. J.
    Wang, S. J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1030 - 1031
  • [33] Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
    Ishigooka, Jun
    Kato, Tadafumi
    Miyajima, Mari
    Watabe, Kei
    Masuda, Takahiro
    Hagi, Katsuhiko
    Higuchi, Teruhiko
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 281 : 160 - 167
  • [34] Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.
    Ferris, SH
    Schmitt, FA
    Doody, RS
    Moebius, H
    Stoeffler, A
    Reisberg, BJ
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S77 - S78
  • [35] Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study)
    Yoon, Soo J.
    Choi, Seong H.
    Na, Hae R.
    Park, Kyung-Won
    Kim, Eun-Joo
    Han, Hyun J.
    Lee, Jae-Hong
    Shim, Young S.
    Na, Duk L.
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2017, 17 (03) : 494 - 499
  • [36] Safety of galantamine and memantine in combination usage in the treatment of mild to moderate Alzheimer's disease
    Ramaswamy, K
    Amatniek, J
    Zhu, Y
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S298 - S298
  • [37] The safety of combined galantamine-memantine treatment in mild to moderate Alzheimer's disease
    Ramaswamy, K.
    Amatniek, J.
    Crivera, C.
    Rupnow, M.
    Zhu, Y.
    Hammond, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 68 - 68
  • [38] Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease
    Bennett, James
    Burns, Jeffrey
    Welch, Paul
    Bothwell, Rebecca
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (04) : 1179 - 1187
  • [39] Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study
    Vivash, Lucy
    Malpas, Charles B.
    Hovens, Christopher M.
    Brodtmann, Amy
    Collins, Steven
    Macfarlane, Stephen
    Velakoulis, Dennis
    O'Brien, Terence J.
    BMJ NEUROLOGY OPEN, 2021, 3 (02)
  • [40] Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
    Doody, Rachelle S.
    Ferris, Steven
    Salloway, Stephen
    Sun, Yijun
    Goldman, Robert
    Xu, Yikang
    Gao, Jeff
    Murthy, Anita K.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2010, 25 (02): : 155 - 159
12345